Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fingolimod in acute ischemic stroke
IRCT20220423054619N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke comparing Standard care + fingolimod with Standard care + placebo (2 arms). Primary endpoints: National Institutes of Health Stroke Scale and Modified Rankin Scale. Started May 2022; status: completed.
02
Drugs
fingolimod
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on IRCT20220423054619N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220423054619N1.